Drugs / EDP1867
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04927195 | Feb 2021 → Feb 2022 | asthma, atopic eczema, psoriasis | Evelo Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP1867 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927195 ↗ |
| Modality | Other / unclassified | “pharmaceutical preparation of a single strain of bacteria” NCT04927195 ↗ |
| Route | Oral | “orally administered” NCT04927195 ↗ |